Placebo (ziltivekimab C)

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Cardiovascular RiskChronic Kidney DiseaseHeart failure with mildly reduced or preserved ejection fraction and systemic inflammationInflammation

Phase 3

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

CompletedNCT05021835

Novo Nordisk A/SCardiovascular Risk, Chronic Kidney Disease, Inflammation

Start: 2021-08-30End: 2026-06-09Updated: 2026-07-28

ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Active, not recruitingCTIS2023-506988-34-00

Novo Nordisk A/SHeart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Start: 2024-03-27Target: 318Updated: 2026-01-23

Related Papers

Editorial: Cardiovascular calcification: disease mechanisms, clinical phenotypes and therapeutic strategies

Frontiers in Cardiovascular Medicine2026-03-27

Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction.

2026-01-01

Impact of Platelet-to-HDL-Cholesterol Ratio on Long-Term Mortality in Coronary Artery Disease Patients with or Without Type 2 Diabetes: Insights from a Chinese Multicenter Cohort

Journal of Inflammation Research2024-05-0111 citations

Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE)

Journal of the American Society of Nephrology2023-12-1318 citations